Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magnesium isoglycyrrhizinate injection for acute drug-induced liver injury
ChiCTR1800016669Phase 3Completed
- Sponsor
- National Pharmaceutical Clinical Research Institute
- Start
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Magnesium isoglycyrrhizinate and tiopronin in Drug-induced hepatitis (DILI) (2 arms), sponsored by National Pharmaceutical Clinical Research Institute. Primary endpoints: Alanine aminotransferase level at week 2, Aspartate aminotransferase level at week 2 and 2 more. Started Dec 2009; status: completed.
02
Drugs
Magnesium isoglycyrrhizinatetiopronin
03
Conditions
Drug-induced hepatitis (DILI)
Beyond the preview
Go deeper on ChiCTR1800016669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016669.